S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in

Genprex Stock Forecast, Price & News

-0.53 (-9.40 %)
(As of 03/3/2021 12:00 AM ET)
Today's Range
Now: $5.11
50-Day Range
MA: $5.30
52-Week Range
Now: $5.11
Volume1.23 million shs
Average Volume1.77 million shs
Market Capitalization$221.15 million
P/E RatioN/A
Dividend YieldN/A
Genprex, Inc. operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism of action to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis and programmed cell death in cancer cells; modulate immune response against cancer cells; and block mechanisms that create drug resistance. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Genprex logo


Genprex Announces Formation of Clinical Advisory Board
February 8, 2021 |  finance.yahoo.com
Genprex Recognizes World Cancer Day - Yahoo Finance
February 5, 2021 |  finance.yahoo.com
Genprex Recognizes World Cancer Day - Business Wire
February 4, 2021 |  businesswire.com
Genprex Recognizes World Cancer Day
February 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GNPX
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share


Net Income$-10,650,000.00


Market Cap$221.15 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.98 out of 5 stars

Medical Sector

1164th out of 1,968 stocks

Pharmaceutical Preparations Industry

528th out of 772 stocks

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.53 (-9.40 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Genprex (NASDAQ:GNPX) Frequently Asked Questions

Is Genprex a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Genprex stock.
View analyst ratings for Genprex
or view top-rated stocks.

What stocks does MarketBeat like better than Genprex?

Wall Street analysts have given Genprex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Genprex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genprex?

Genprex saw a decrease in short interest in the month of February. As of February 12th, there was short interest totaling 3,270,000 shares, a decrease of 22.0% from the January 28th total of 4,190,000 shares. Based on an average trading volume of 1,720,000 shares, the days-to-cover ratio is presently 1.9 days.
View Genprex's Short Interest

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Genprex

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Monday, April, 1st. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.10.
View Genprex's earnings history

How has Genprex's stock been impacted by COVID-19 (Coronavirus)?

Genprex's stock was trading at $2.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNPX stock has increased by 111.2% and is now trading at $5.11.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GNPX?

3 analysts have issued 1 year price objectives for Genprex's shares. Their forecasts range from $5.00 to $7.00. On average, they expect Genprex's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for Genprex
or view top-rated stocks among Wall Street analysts.

Who are Genprex's key executives?

Genprex's management team includes the following people:
  • Mr. John Rodney Varner, Co, Founder, Pres, CEO, Sec. & Chairman (Age 64, Pay $429.68k)
  • Mr. Ryan M. Confer, Chief Financial Officer (Age 39, Pay $341.71k)
  • Mr. Michael T. Redman, Exec. VP & COO (Age 66)
  • Ms. Catherine M. Vaczy, Exec. VP, Gen. Counsel & Chief Strategy Officer (Age 60)
  • Mr. Thomas C. Gallagher Esq., Sr. VP of Intellectual Property & Licensing
  • Dr. Jack A. Roth F.A.C.S., FACS, M.D., Chairman of Scientific & Medical Advisory Board

Who are some of Genprex's key competitors?

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.92%), Northern Trust Corp (0.86%), Wells Fargo & Company MN (0.29%), Nuveen Asset Management LLC (0.23%), Bank of New York Mellon Corp (0.23%) and First Trust Advisors LP (0.22%).
View institutional ownership trends for Genprex

Which institutional investors are selling Genprex stock?

GNPX stock was sold by a variety of institutional investors in the last quarter, including IHT Wealth Management LLC, Price T Rowe Associates Inc. MD, Barclays PLC, and First Trust Advisors LP.
View insider buying and selling activity for Genprex
or view top insider-selling stocks.

Which institutional investors are buying Genprex stock?

GNPX stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., JPMorgan Chase & Co., QS Investors LLC, Bank of New York Mellon Corp, Virtu Financial LLC, Resources Investment Advisors LLC., and Northern Trust Corp.
View insider buying and selling activity for Genprex
or or view top insider-buying stocks.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $5.11.

How much money does Genprex make?

Genprex has a market capitalization of $221.15 million. The company earns $-10,650,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does Genprex have?

Genprex employs 8 workers across the globe.

What is Genprex's official website?

The official website for Genprex is www.genprex.com.

Where are Genprex's headquarters?

Genprex is headquartered at 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-537-7997 or via email at [email protected]

This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.